Physician profile
Chaitali Singh Nangia
NPI 1669425286
$697,242.47
in general payments reported to CMS, 2019-2025
68 companies · $131K in 2025
The $131K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95K · 2020: $22K · 2021: $79K · 2022: $87K · 2023: $125K · 2024: $159K · 2025: $131K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $301K · Consulting Fee: $54K · Travel and Lodging: $50K · Food and Beverage: $8,547 · Education: $21.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $301,349.23 |
| Consulting Fee | $54,295.50 |
| Travel and Lodging | $50,472.10 |
| Food and Beverage | $8,546.79 |
| Education | $21.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $215,010.13 | 2019-2025 | Libtayo |
| Gilead Sciences, INC. | $136,411.70 | 2021-2025 | Trodelvy |
| Stemline Therapeutics INC. | $107,999.20 | 2019-2025 | Orserdu |
| Novartis Pharmaceuticals Corporation | $95,930.90 | 2019-2025 | |
| Genzyme Corporation | $61,152.02 | 2019-2023 | |
| Coherus Oncology, INC. | $34,044.11 | 2020-2025 | Loqtorzi |
| Lilly USA, LLC | $17,894.04 | 2019-2023 | Retevmo, Jaypirca |
| Astrazeneca Pharmaceuticals Lp | $7,777.18 | 2020-2025 | Enhertu, Truqap, Tagrisso |
| Eli Lilly and Company | $4,375.00 | 2022-2024 | Verzenio |
| Astrazeneca Uk Limited | $3,915.00 | 2024-2025 | Lynparza |
| Seagen INC. | $2,177.46 | 2019-2023 | Tukysa, Padcev |
| Pfizer INC. | $1,681.74 | 2019-2024 | |
| Exelixis INC. | $1,281.25 | 2022-2023 | Cabometyx |
| Amgen INC. | $990.25 | 2019-2023 | Lumakras, Vectibix, Xgeva |
| Merck Sharp & Dohme LLC | $791.53 | 2019-2023 | Keytruda, Lynparza |
Show all 64 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chaitali Nangia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.